What Is Claimed Is:

~~1. (*S*)-bupropion that is at least 95% enantiomerically pure for use in therapy, wherein the (*S*)-bupropion is to be orally administered in a dosage form one or two times per day to a human being.~~

~~2~~1. Use of (*S*)-bupropion that is at least 95% enantiomerically pure in the manufacture of a medicament for treating a neurological disorder or a central nervous system disorder in a human being, wherein the medicament is to be orally administered in a dosage form one or two times per day to the human being, wherein the dosage form includes 80 mg to 120 mg of the (S)-bupropion, and wherein the dosage form is more effective than administration of a dosage form including the same amount of (R)-bupropion in treating the same condition in the human being.

~~3~~2. A kit comprising a dosage form and a label, wherein the dosage form comprises (*S*)-bupropion that is at least 95% enantiomerically pure, and the label states that the dosage form is to be orally administered one or two times per day to a human being for treating a condition in the human being, wherein the dosage form includes 80 mg to 120 mg of the (S)-bupropion, and wherein the dosage form is more effective than administration of a dosage form including the same amount of (R)-bupropion in treating the same condition in the human being.

~~4~~3. The kit of claim ~~3~~2, wherein the condition is a neurological disorder or a central nervous system disorder.

~~5~~4. The kit of claim ~~4~~3, wherein the human being is selected for having the condition.

~~6~~5. The use of claim ~~2~~1, or the kit of any one of claims ~~3-5~~2-4, wherein the (*S*)-bupropion is to be administered once daily.

~~7~~6. The use of claim ~~2~~1, or the kit of any one of claims ~~3-5~~2-4, wherein the (*S*)-bupropion is to be administered in two doses per day, and wherein the sum of the two doses per day is a daily dose.

~~8~~7. The use of any one of claims 1, 5, or 6~~2, 6, or 7~~, or the kit of any one of claims 2-6~~3-7~~, wherein the (*S*)-bupropion is to be administered for at least 8 consecutive days.

~~9~~8. The use of any one of claims 1, 5, or 6~~2, 6, or 7~~, or the kit of any one of claims 2-6~~3-7~~, wherein the (*S*)-bupropion is to be administered for at least 14 consecutive days.

~~10~~9. The use of any one of claims 1, 5, or 6~~2, 6, or 7~~, or the kit of any one of claims 2-6~~3-7~~, wherein the (*S*)-bupropion is to be administered for at least 21 consecutive days.

~~11~~10. The use of any one of claims 1, 5, or 6~~2, 6, or 7~~, or the kit of any one of claims 2-6~~3-7~~, wherein the (*S*)-bupropion is to be administered for at least 28 consecutive days.

~~12~~11. The use of any one of claims 1 or 5-10~~2 or 6-11~~, or the kit of any one of claims 2-10~~3-11~~, wherein the dosage form provides sustained release of the (*S*)-bupropion.

~~13~~12. The use of claim 11~~12~~, or the kit of claim 11~~12~~, wherein the dosage form is formulated to have a T_{max} of (*S*)-bupropion that is ~~about~~ 2 hours to ~~about~~ 4 hours.

~~14~~13. The use of any one of claims 1 or 5-12~~2 or 6-13~~, or the kit of any one of claims 2-12~~3-13~~, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is at least about 300 ng·hr/mL.

~~15~~14. The use of any one of claims 1 or 5-12~~2 or 6-13~~, or the kit of any one of claims 2-12~~3-13~~, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is at least about 400 ng·hr/mL.

~~16~~15. The use of any one of claims 1 or 5-14~~2 or 6-15~~, or the kit of any one of claims 2-14~~3-15~~, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is ~~about~~ 500 ng·hr/mL to ~~about~~ 900 ng·hr/mL.

~~17~~16. The use of any one of claims 1 or 5-15~~2 or 6-16~~, or the kit of any one of claims 2-15~~3-16~~, wherein the dosage form provides a C_{max} of (*S*)-bupropion in the human being that is ~~about~~ 60 ng/mL to ~~about~~ 140 ng/mL.

17. The use of any one of claims 1 or 5-15, or the kit of any one of claims 2-15, wherein the dosage form is substantially free of any active pharmaceutical ingredients other than (S)-bupropion.